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Dr Michael T. Caps (Honolulu, Hawaii). I would like to
congratulate the authors for a thought-provoking study and a
well-written manuscript and I would like to thank them for early
delivery of the manuscript for my review.
This study attempts to answer the following two questions: 1)
Among patients undergoing femoropopliteal stent placement, is
there an association between preprocedural TASC classification
and stent failure? and 2) Among those suffering stent failure, is
there an association between preprocedural TASC classification
and other outcomes, including the loss of tibial run-off vessels, the
mechanism (stenosis vs occlusion) of stent failure, and the need for
subsequent open revascularization?
The answer to both questions is “yes”. The authors have
demonstrated an association between the preprocedural TASC
classification and femoropopliteal stent failure, consistent with
previously published studies. They found that patients with more
advanced preprocedural TASC lesions were more likely to suffer
stent failure, more likely to lose tibial run-off vessels when they
failed, more likely to occlude than narrow as their mechanism of
failure, more likely to require open revascularization, and when
they required open revascularization, more likely to require mod-
ification of the operative plan to a more distal anastomotic site for
bypass.
So what does this all mean and how should we modify our
approach to our patients as a result of these findings, if at all? A
more fundamental but implicit question the authors appear to be
investigating is whether certain patients with more advanced in-
frainguinal disease are better served by avoiding endovascular
treatment altogether and proceeding directly to open revascular-mong TASC C and D patients with long-term follow up and
ssessment of clinical as well as anatomic outcomes. Since high
uality studies of this type are not available, we are forced to try to
lean as much information as we can from well-conducted obser-
ational studies such as this one.
I have the following questions for the authors:
. In the manuscript, you state that in your practice, patients with
orificial SFA occlusion and total SFA/popliteal/proximal tibial
occlusion are treated with surgery. As a result of your study,
which other patient populations with femoropopliteal occlusive
disease do you feel should go directly to surgery? Are there
certain types of TASC C/D patients that should go directly to
surgery? Patients with long occlusions and limited run-off?
Patients with long SFA and above-knee popliteal occlusion
whom you risk converting from a femoropopliteal bypass to a
femorotibial bypass? Those with more extensive tissue damage
in the foot? Others?
. What do you believe is the mechanism of tibial artery occlusion
in the patients who suffered stent failure? You suggest a com-
mon mechanism may be thromboembolism occurring at the
time of stent occlusion, yet there are other potential causes.
Patients with long SFA/popliteal occlusions who are recana-
lized are more likely to embolize during the recanalization.
Could they have lost tibial arteries during the initial stenting
procedure? Patients with TASC C/D lesions may also have
more virulent atherosclerosis and may be more prone to de-
velop atherosclerosis disease progression. Is it possible these
patients would have suffered progressive loss of tibials over time
even if they hadn’t been stented?. The strong association you demonstrated between hypercho-
lesterolemia and stent failure was compelling. In addition to
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Volume 53, Number 3 Gur et al 667plavix and aspirin, do you also place your stented patients on a
statin?
4. What fraction of the stent failures were associated with stent
fractures? There is data suggesting that for TASC C and D
lesions, covered stents such as Viabahnmay perform better than
open-cell nitinol stents, perhaps because they are less prone to
stent fracture, particularly in the distal SFA and popliteal arter-
ies. What types of stents were used in this study and were
particular types of stents and particular stent locations more
prone to failure?
Once again, I would like to congratulate the authors for a
well-done study.
Dr William M. Lee. We would like to thank Dr Caps for his
insightful commentary and review. We will attempt to answer his
questions in order.
It is generally well accepted that patients with TASC C/D
lesions who are of reasonable operative risk and have good conduit
should be considered for open revascularization first. In particular,
since failures in the TASC C/D stents in our analysis were more
likely to be accompanied by loss of run-off, patients with only one
or two patent tibial vessels on initial angiography should be
strongly considered for surgical bypass as initial treatment.
The mechanism of loss of run-off remains unclear. Our
practice is to routinely perform run-off angiography immedi-
ately preceding and immediately after angioplasty and stenting. ws a result, we know that tibial run-off was never lost during the
nitial intervention. We agree that thromboembolism and the
atural progression of atherosclerotic disease are the likely
ulprits. Although we did not include analysis of this, a substan-
ial number of our patient population had arterial duplex exam-
nation confirming unchanged tibial run-off in the months prior
o loss of patency, and change in run-off only in conjunction
ith a change in patency. Whether this represents emboli from
he stent occlusion causing a loss of tibial vessels, or perhaps a
atural worsening of the run-off causing patency problems in
he stent is unknown.
Indeed, risk factor modification and pharmacotherapy remain
ainstays of noninterventional treatment. We consider statin ther-
py a vital component of the medical treatment for atherosclerotic
cclusive vascular disease, and work with the referring physicians to
nsure that all patients are adequately treated.
Only three stent fractures in our series were seen, and all were
ssociated with Luminex stents used early in our experience.We no
onger employ these stents in our practice. We have begun incor-
orating the use of the Viabahn stent graft, particularly for long
egment occlusions, but intentionally excluded them from this
eries. When our experience becomes large enough, we hope to
erform a comparative review of those outcomes as well. We were
ot able to define any particular type of stent or stent location that
as more prone to failure.
